Suppr超能文献

重塑终末期肝病模型以预测肝硬化合并急性肾损伤重症患者的死亡风险。

Remodeling the model for end-stage liver disease for predicting mortality risk in critically ill patients with cirrhosis and acute kidney injury.

作者信息

Zhou Xiao-Dong, Chen Qin-Fen, Sun Dan-Qin, Zheng Chen-Fei, Liang Dong-Jie, Zhou Jian, Wang Song-Jie, Liu Wen-Yue, Van Poucke Sven, Wang Xiao-Dong, Shi Ke-Qing, Huang Wei-Jian, Zheng Ming-Hua

机构信息

Department of Cardiovascular Medicine Heart Center, First Affiliated Hospital of Wenzhou Medical University Wenzhou China.

Department of Gastroenterology First Affiliated Hospital of Wenzhou Medical University Wenzhou China.

出版信息

Hepatol Commun. 2017 Aug 1;1(8):748-756. doi: 10.1002/hep4.1076. eCollection 2017 Oct.

Abstract

Serum creatinine measurement demonstrates a poor specificity and sensitivity for the early diagnosis of acute kidney injury (AKI) in patients with cirrhosis. The existing model for end-stage liver disease (MELD) score reveals multiple pitfalls in critically ill patients with cirrhosis and acute kidney injury (CAKI). The aim of this study was to re-evaluate the role of creatinine values in the existing MELD score and to develop a novel score for CAKI, named the "acute kidney injury-model for end-stage liver disease score" (AKI-MELD score). We extracted 651 CAKI from the Multiparameter Intelligent Monitoring in Intensive Care database. A time-dependent Cox regression analysis was performed for developing remodeled MELD scores (Reweight-MELD score, Del-Cr-MELD score, and AKI-MELD score). The area under the receiver operating characteristic curve provided the discriminative power of scoring models related to outcome. The hazard ratio of creatinine was 1.104 (95% confidence interval [CI], 0.945-1.290; = 0.211). Reweight-MELD score and Del-Cr-MELD score (decreasing the weight of creatinine) were superior to the original MELD score (all < 0.001). The new AKI-MELD score consists of bilirubin, the international normalized ratio, and the ratio of creatinine in 48 hours to creatinine at admission. It had competitive discriminative ability for predicting mortality (area under the receiver operating characteristic curve, 0.720 [95% CI, 0.653-0.762] at 30 days, 0.688 [95% CI, 0.630-0.742] at 90 days, and 0.671 [95% CI, 0.612-0.725] at 1 year). Further, AKI-MELD score had significantly higher predictive ability in comparison with MELD score, MELD-Na score, and Updated MELD score (all < 0.001). : The predictive value of creatinine for CAKI should be re-evaluated. AKI-MELD score is a potentially reliable tool to determine the prognosis for mortality of CAKI. ( 2017;1:748-756).

摘要

血清肌酐测量对于肝硬化患者急性肾损伤(AKI)的早期诊断特异性和敏感性较差。现有的终末期肝病模型(MELD)评分在肝硬化合并急性肾损伤(CAKI)的危重症患者中存在多个缺陷。本研究的目的是重新评估肌酐值在现有MELD评分中的作用,并开发一种针对CAKI的新评分,即“急性肾损伤-终末期肝病评分”(AKI-MELD评分)。我们从重症监护多参数智能监测数据库中提取了651例CAKI患者。进行了时间依赖性Cox回归分析以建立重塑的MELD评分(重新加权MELD评分、肌酐校正MELD评分和AKI-MELD评分)。受试者工作特征曲线下面积提供了与结局相关的评分模型的判别能力。肌酐的风险比为1.104(95%置信区间[CI],0.945-1.290;P = 0.211)。重新加权MELD评分和肌酐校正MELD评分(降低肌酐权重)优于原始MELD评分(均P < 0.001)。新的AKI-MELD评分由胆红素、国际标准化比值以及48小时肌酐与入院时肌酐的比值组成。它在预测死亡率方面具有竞争性的判别能力(30天时受试者工作特征曲线下面积为0.720 [95% CI,0.653-0.762],90天时为0.688 [95% CI,0.630-0.742],1年时为0.671 [95% CI,0.612-0.725])。此外,与MELD评分、MELD-Na评分和更新的MELD评分相比,AKI-MELD评分具有显著更高的预测能力(均P < 0.001)。结论:应重新评估肌酐对CAKI的预测价值。AKI-MELD评分是确定CAKI患者死亡预后的潜在可靠工具。(2017;1:748-756)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6451/5678914/e73f7d40f044/HEP4-1-748-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验